PPARA and primary biliary cholangitis: Clinical trials are evaluating PPARα activation for treating non-alcoholic fatty liver disease and primary biliary cirrhosis, in combination with existing treatments (ClinicalTrials.gov identifier: NCT00262964, NCT00575042, NCT02823353, NCT02965911, NCT02823366).